Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with insidious onset, insensitive to chemotherapy and poor prognosis, which make its clinical treatment face an enormous challenge. In recent years, with the rapid development of nanotechnology, increasing kinds of nanomedicine come to the forefront in biomedical fields. Through rational design, nanomedicine can be prepared in suitable size and modified with specific liver targeting ligands. Moreover, various therapeutic agents of different mechanisms can be co-loaded into the same nanosystem, thus achieving the synergistic therapeutic effects towards HCC. Nanomedicine is able to enhance drug bioavailability and liver-targeting effect as well as reduce the side effects to normal tissues, which provide a great potential in HCC therapy. This review summarizes the recent progress in the application of nanomedicine for HCC therapy from two aspects: their liver-targeting design strategies and the recent progress in combination therapy of HCC.
肝癌是全球范围内最常见的一种恶性肿瘤，具有发病隐匿、化疗不敏感、预后差等特点，给其临床治疗带来了严峻的挑战。近年来，随着纳米技术的发展，越来越多的纳米药物被开发应用于生物医学领域。通过合理的设计，纳米药物可被制备成具有适宜尺寸、表面修饰特异性肝癌靶向配体以及同时负载多种不同作用机制的治疗剂，从而提高药物的生物利用度，增强对肝癌的靶向性，降低对正常组织的毒副作用，为肝癌的治疗提供了新的希望。本文将对纳米药物的靶向设计策略及其在联合治疗肝癌的研究进展等方面进行综述。.
Keywords: combination therapy; hepatocellular carcinoma; nanomedicine; targeting.